Compare Salesforce Inc (CRM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Incyte Corporation — how do they compare? Salesforce Inc trades at $228.92 (market cap $187.48B), while Incyte Corporation trades at $113.37 (market cap $22.85B). The key difference: Salesforce Inc is far larger — about 8.2× Incyte Corporation's market cap, and Salesforce Inc pays a 0.77% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Incyte Corporation for 33 Days on average.
| CRM | INCY | |
|---|---|---|
Market Cap | $187.48B | $22.85B |
Volume | 6,155,822 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $266.23 | $129.93 |
52-Week Low | $150.12 | $83.80 |
Typical Hold Time | 89 Days | 33 Days |
Enterprise Value | $217.82B | $18.35B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $228.19, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 77.3% gross margins and 22% net income margin. Recent news highlights AI-driven growth potential despite sector-wide software stock volatility. Analyst consensus remains strongly bullish with a $271.91 price target, representing 19% upside potential from current levels.
CRM presents a compelling opportunity with strong profitability and AI monetization driving growth, though technical weakness and sector headwinds pose near-term risks. The company's rule of 44 performance and expanding free cash flow support long-term upside, but investors should monitor competitive pressures and macroeconomic conditions affecting software valuations.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
